文献类型：期刊文献

英文题名：A Randomized Controlled Trial on the Effectiveness of Dextran Oral Liquid in the Treatment of Nutritional Iron Deficiency Anemia in Children

作者：Sun, Zhiqian[1];Luo, Fengxia[1];Feng, Peng[1];Luo, Wenzhen[1];Wang, Ning[1];Ge, Kunzu[1];Liu, Qing[1];Shi, Zhenggang[1]

第一作者：Sun, Zhiqian

通信作者：Shi, ZG[1]

机构：[1]Gansu Univ Chinese Med, Clin Coll Tradit Chinese Med, Dept Pediat, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学中医临床学院

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Clin Coll Tradit Chinese Med, Dept Pediat, Lanzhou 730000, Gansu, Peoples R China.|[10735ccd4a8840d96ab71]甘肃中医药大学中医临床学院;[10735]甘肃中医药大学;

年份：2023

卷号：37

期号：6

起止页码：2897

外文期刊名：JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS

收录：;Scopus(收录号：2-s2.0-85167356954);WOS:【SCI-EXPANDED(收录号:WOS:001035716100001)】；

语种：英文

外文关键词：iron dextran oral liquid; nutritional iron deficiency; anemia; children

摘要：Background & Objective: Nutritional iron deficiency anemia (NIDA) is caused by decreased hemoglobin biosynthesis due to iron deficiency. It is the most common anemia in children, and a serious danger to health. This study was aimed at investigating the efficacy of iron dextran oral solution in children with NIDA.Methods: This is a prospective randomized controlled trial on 70 children with NIDA from August 2020 to September 2021. The enrolled subjects were divided into group A and group B, with 35 children in each group. Group A received ferrous sulfate oral solution, while group B received iron dextran oral solution. Hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), clinical treatment outcomes, and adverse events were determined and compared between theResults: Group B had higher levels of hemoglobin, MCHC and MCV than group A (p < 0.05). Moreover, group B had significantly higher total treatment effectiveness and lower incidence of adverse reactions than group A (p < 0.05).Conclusions: The use of iron dextran oral solution is a promising strategy in the treatment of children with NIDA. It alleviates symptoms of NIDA and optimizes hemoglobin, MCHC and MCV, and it has a favorable safety profile. Therefore, iron dextran oral solution is suitable for clinical application for treatment of NIDA.